Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
decrease depressive » increasing depressive (Expand Search), decreased expression (Expand Search)
mean decrease » a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
Showing 21 - 40 results of 45,472 for search '(( significant decrease depressive ) OR ( significant ((we decrease) OR (mean decrease)) ))', query time: 0.95s Refine Results
  1. 21
    Table_1_Regional decreases of cortical thickness in major depressive disorder and their correlation with illness duration: a case-control study.DOCX

    Table_1_Regional decreases of cortical thickness in major depressive disorder and their correlation with illness duration: a case-control study.DOCX by Fukun Wang (14131377)

    Published 2024
    “…</p>Results<p>Compared with the HC group, patients with MDD had significantly decreased cortical thickness, in left pars triangularis, left pars orbitalis, left rostral middle frontal gyrus, left supramarginal gyrus, right parahippocampal gyrus, right lingual gyrus, right fusiform and right inferior parietal gyrus. …”
    Save to List
    Saved in:
  2. 22
    CUMS, smoke or their combination increased pro-inflammatory cytokines production, but decreased peripheral mononuclear cells viability after stimulated by LPS or ConA.

    CUMS, smoke or their combination increased pro-inflammatory cytokines production, but decreased peripheral mononuclear cells viability after stimulated by LPS or ConA. by Bai-Ping Liu (14164799)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 23
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 24
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 25
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 26
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 27
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 28
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 29
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 30
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 31
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 32
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 33
    Estimated changes in follow-up depressive symptoms associated with 60-minute reallocations from the mean baseline movement behaviour composition<sup>b'*'</sup>.

    Estimated changes in follow-up depressive symptoms associated with 60-minute reallocations from the mean baseline movement behaviour composition<sup>b'*'</sup>. by Hugues Sampasa-Kanyinga (606145)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  14. 34
    Data sample demographics. Note that AP refers to anti-psychotic medication, and AD refers to anti-depressive medication. Thus, AP and AD in this table refer to the percentage of patients taking anti-psychotic and anti-depressive medication, respectively. PANSS is a symptom scale for schizophrenia. We show its positive, negative, and composite scores.

    Data sample demographics. Note that AP refers to anti-psychotic medication, and AD refers to anti-depressive medication. Thus, AP and AD in this table refer to the percentage of pa... by Eloy Geenjaar (21533195)

    Published 2025
    Save to List
    Saved in:
  15. 35
    Flow chart of participant inclusion from NHANES 2005–2018 surveys.

    Flow chart of participant inclusion from NHANES 2005–2018 surveys. by Vanessa K. Tassone (13190695)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 36
    Demographic characteristics of the NHANES 2005–2018 study population (<i>n</i> = 23,669), stratified by sex and employment status.

    Demographic characteristics of the NHANES 2005–2018 study population (<i>n</i> = 23,669), stratified by sex and employment status. by Vanessa K. Tassone (13190695)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 37
    Reason for unemployment among those unemployed in the study population, stratified by sex.

    Reason for unemployment among those unemployed in the study population, stratified by sex. by Vanessa K. Tassone (13190695)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 38
    Adjusted logistic regression of suicidal ideation and educational attainment, stratified by sex and employment status (study population).

    Adjusted logistic regression of suicidal ideation and educational attainment, stratified by sex and employment status (study population). by Vanessa K. Tassone (13190695)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 39
    Adjusted logistic regression of depressive symptoms and educational attainment, stratified by sex and employment status (study population).

    Adjusted logistic regression of depressive symptoms and educational attainment, stratified by sex and employment status (study population). by Vanessa K. Tassone (13190695)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 40
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: